Age-related Macular Degeneration Clinical Trial
Official title:
Remapping the Visual Field to Aid Reading With Central Scotomas
Reading performance in patients with Central Vision Loss and age matched controls with artificial scotomas will be measured with and without different kinds of remapping of missing text to different parts of the visual field.
Status | Recruiting |
Enrollment | 108 |
Est. completion date | November 30, 2024 |
Est. primary completion date | November 30, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: 1. 16 years or older 2. Central vision loss of at least 5 deg diameter, including the fovea, from bilateral central scotomas 3. Stable fixation (+/- 1 deg) using their PRL. 4. No cognitive impairment as indicated by a Mini-Mental State Examination (MMSE). 5. Satisfactory calibration achievable using eye tracker Exclusion Criteria: 1. Central vision loss of less than 5 deg diameter; scotomas that do not cover the fovea; unilateral scotomas 2. Poor fixation (worse than+/- 1 deg) using their PRL. 3. Cognitive impairment as indicated by a Mini-Mental State Examination (MMSE). 4. Satisfactory calibration not achievable using eye tracker |
Country | Name | City | State |
---|---|---|---|
United States | University of Minnesota | Minneapolis | Minnesota |
Lead Sponsor | Collaborator |
---|---|
University of Minnesota |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reading Speed for Individual Words | How quickly participants can correctly read displayed text | Measured during third visit- each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day | |
Primary | Reading Speed for Sentences | How quickly participants can correctly read displayed text | Measured during fourth visit- each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day | |
Primary | Reading Speed for Natural Text Samples | How quickly participants can correctly read displayed text | Measured during fifth visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day | |
Primary | Reading error rate for Individual Words | How many mistakes participants make | Measured during third visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day | |
Primary | Reading error rate for Sentences | How many mistakes participants make | Measured during fourth visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day | |
Primary | Reading error rate for Natural Text Samples | How many mistakes participants make | Measured during fifth visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day | |
Secondary | Eye fixation quality for words | Variance of x and y eye position coordinates computed during fixation periods while reading | Measured during third visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day | |
Secondary | Eye fixation quality for sentences | Variance of x and y eye position coordinates computed during fixation periods while reading | Measured during fourth visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day | |
Secondary | Eye movement quality for sentences | Number off leftward (regressive) eye movements during sentence reading | Measured during fourth visit | |
Secondary | Eye fixation quality for natural text samples | Variance of x and y eye position coordinates computed during fixation periods while reading | Measured during fifth visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day | |
Secondary | Eye movement quality for natural text samples | Number off leftward (regressive) eye movements during natural text reading | Measured during fifth visit; each visit is one day only and this measure refers to data gathered during a < 1 hr long reading session during that day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05984927 -
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05536297 -
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
|
Phase 3 | |
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Completed |
NCT04005352 -
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
|
Phase 3 | |
Withdrawn |
NCT02873351 -
A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration
|
Phase 2 | |
Active, not recruiting |
NCT02802657 -
Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration
|
Phase 4 | |
Not yet recruiting |
NCT02864472 -
Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose
|
Phase 4 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT01445548 -
Sirolimus for Advanced Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT02035722 -
Intravitreal Injections-related Anxiety
|
Phase 2/Phase 3 | |
Completed |
NCT01175395 -
20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01048476 -
Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01174407 -
Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration
|
N/A | |
Terminated |
NCT00712491 -
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT00345176 -
Age-Related Eye Disease Study 2 (AREDS2)
|
Phase 3 | |
Completed |
NCT02140151 -
Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT02555306 -
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Recruiting |
NCT04796545 -
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
|
N/A | |
Completed |
NCT03166202 -
Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator
|
||
Completed |
NCT01397409 -
Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
|
Phase 2 |